突破性发作的风险取决于的类型和病因
Jakob I Doerrfuss1,2, Luise Graf1, Thea Hüsing1
1Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology with Experimental Neurology, Berlin, Germany.
Epilepsia
|June 29, 2024
概括
患有发作自由症的患者可能根据类型有不同的突破性发作风险. 继缺血性中风后的,与其他类型相比,突破性发作的风险较低.
科学领域:
- 神经学 神经学
- 发病学 (Epileptology) 是一个专业的学科.
背景情况:
- 在患者中,尽管服用抗发作药物 (ASM),但仍可能发生突破性发作.
- 突破性发作的风险可能因潜在的类型和病因而异.
- 了解这些变异对于患者的咨询和预后至关重要.
研究的目的:
- 研究是否突破性发作率在不同类型和病因方面不同,在至少12个月没有发作的患者中.
- 测试后缺血性中风有突破性发作的风险降低的假设.
主要方法:
- 从第三级诊所对521名患者的回顾性分析.
- 突破性发作被定义为在ASM治疗期间经过>=12个月的无发作后的未引起的发作.
- 单变量和多变量分析确定了与突破性发作相关的因素.
主要成果:
- 29%的患者经历了突破性发作后的中位数是34个无月.
- 缺血性中风后 (OR=.267) 和遗传性泛性 (OR=.559) 与更低的突破性发作风险有关.
- 智力障碍 (OR=2.768) 和尝试ASM的数量 (OR=1.203) 增加了突破性发作风险.
结论:
- 这项研究是首次将类型/病因与突破性发作风险联系起来.
- 患有更容易发作的发病者表现出更低的突破性发作风险.
- 这些发现有助于更好地向没有的患者提供关于长期预后的咨询.
更多相关视频
相关概念视频
Seizures: Classification
331
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
331
Arteries of the Lower Limbs
186
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
186
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
285
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
285
Antiepileptic Drugs: Sodium Channel Blockers
503
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
503
Antiepileptic Drugs: Calcium Channel Blockers
364
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
364
Antiepileptic Drugs: GABAergic Pathway Potentiators
382
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
382


